消风散加减方联合依巴斯汀治疗风热犯表型荨麻疹的临床观察
发布时间：2018-08-02 15:26
【摘要】：目的采用消风散加减方联合依巴斯汀治疗风热犯表型荨麻疹,综合评价其治疗荨麻疹的症状完全消退时间、瘙痒改善情况、风团数目改善情况、生活质量改善情况、疾病疗效、不良反应及复发率,分析其治疗荨麻疹的优势,探讨中西医结合疗法的治疗效果。方法将63例符合风热犯表型荨麻疹患者按随机数字表法分为治疗组和对照组,治疗组32例,采用口服消风散加减方联合依巴斯汀的方法;对照组31例,采用口服依巴斯汀方法。两组疗程均为两周,分别在治疗7天后、治疗14天后各观察1次疗效,共观察2次。比较两组治疗前后荨麻疹活动度(UAS)评分、皮肤病生活质量(DLQI)评分、同时比较两组患者的荨麻疹症状完全消退时间、瘙痒改善情况、风团数目改善情况、疾病疗效,并注意观察治疗过程中的不良反应以及治疗结束后1个月及3个月内荨麻疹患者的复发率。得出的所有数据均采用SPSS18.0软件进行统计学分析。结果(1)两组治疗前荨麻疹活动度(UAS)评分、风团数目评分、瘙痒症状评分、皮肤病生活质量(DLQI)评分的组间比较均无统计学意义(P0.05),治疗组和对照组在分别治疗7天后、14天后与各自治疗前相比,有显著性差异(P0.01);其中,治疗组和对照组在荨麻疹活动度(UAS)评分、风团数目评分、瘙痒症状评分、皮肤病生活质量评分、疾病疗效方面,治疗14天后与治疗7天的组内比较,均有统计学意义(P0.05)。(2)两组患者治疗7天后荨麻疹活动度(UAS)评分、皮肤病生活质量(DLQI)评分的组间比较差异无统计学意义(P0.05);两组患者治疗7天后疗效比较无统计学意义(P0.05)。(3)两组患者治疗14天后瘙痒症状评分、风团数目评分、荨麻疹活动度(UAS)评分、皮肤病生活质量(DLQI)评分的组间比较均有统计学意义(P0.05)。两组患者治疗14天后疗效比较有统计学意义(P0.05)。治疗组在改善患者的瘙痒症状、风团数目、DLQI评分、UAS评分、疗效等方面均优于对照组。(4)两组荨麻疹患者症状完全消退时间相比较:治疗组荨麻疹患者症状完全消退的平均时间为6.96±2.90天,对照组荨麻疹患者症状完全消退的平均时间为8.95±3.73天;两者相比差异有统计学意义(P0.05)。这表明治疗组在快速改善荨麻疹症状所用时间方面,要优于对照组。(5)两组患者治疗过程中的不良反应分布情况比较无明显差异(P0.05)。(6)两组患者治疗后1个月内的复发率比较无统计学意义(P0.05);治疗后3个月内的复发率比较无统计学意义(P0.05)。结论消风散加减方联合依巴斯汀治疗风热犯表型荨麻疹疗效确切,在快速改善荨麻疹患者瘙痒、消退风团数目、提高生活质量等方面均优于依巴斯汀组,复发率低且无明显不良反应,值得临床进一步推广应用。
[Abstract]:Objective to treat phenotypic urticaria with Xiaofeng Powder and Ebustine, and to evaluate the time of complete regression, the improvement of pruritus, the improvement of the number of wind mass, the improvement of quality of life and the curative effect of the disease in the treatment of urticaria. Adverse reaction and recurrence rate, analysis of its advantages in the treatment of urticaria, explore the therapeutic effect of integrated Chinese and western medicine therapy. Methods Sixty-three patients with urticaria according to phenotype of rheumatic fever were randomly divided into two groups: treatment group (n = 32) and control group (n = 31). The course of treatment in both groups was two weeks. After 7 days and 14 days, the curative effect was observed once and twice respectively. Before and after treatment, the (UAS) score of urticaria activity, the (DLQI) score of quality of life of skin diseases, the time of complete regression of urticaria symptoms, the improvement of pruritus, the improvement of the number of wind masses, and the curative effect of the disease were compared between the two groups. The adverse reactions during treatment and the recurrence rate of urticaria patients within 1 month and 3 months after treatment were observed. All the obtained data were statistically analyzed by SPSS18.0 software. Results (1) before treatment, (UAS) score, wind mass number score, pruritus symptom score were used in the two groups. There was no significant difference in (DLQI) score of skin diseases between the two groups (P0.05). There was a significant difference between the treatment group and the control group after 7 days of treatment and 14 days after treatment compared with that before treatment (P0.01). In the treatment group and the control group, the (UAS) score of urticaria activity, the score of wind mass number, the score of pruritus symptom, the score of quality of life of skin disease, and the curative effect of the disease were compared between the treatment group and the control group after 14 days of treatment and 7 days of treatment. There was significant difference (P0.05). (2) between the two groups after 7 days of treatment of urticaria activity (UAS) score, There was no significant difference in (DLQI) score of skin disease quality of life between the two groups (P0.05), and there was no significant difference in curative effect between the two groups after 7 days of treatment (P0.05). (3). The score of pruritus symptom, the number of wind mass, the (UAS) score of urticaria activity after 14 days of treatment were not statistically significant between the two groups (P0.05). The (DLQI) score of dermatosis quality of life was statistically significant (P0.05). Two groups of patients after 14 days treatment efficacy was statistically significant (P0.05). In the treatment group, the symptoms of pruritus and the number of wind masses were improved by DLQI score and UAS score. (4) the mean time of complete disappearance of symptoms in the treatment group was 6.96 卤2.90 days, and that in the control group was 8.95 卤3.73 days. The difference was statistically significant (P0.05). This suggests that the treatment group took time to quickly improve the symptoms of urticaria. (5) there was no significant difference in the distribution of adverse reactions between the two groups in the course of treatment (P0.05). (6). There was no significant difference in the recurrence rate within one month after treatment between the two groups (P0.05); the recurrence rate within 3 months after treatment had no statistical significance (P0.05). Conclusion the curative effect of Xiaofengsan plus subtractive prescription combined with Ebastine in the treatment of phenotypic urticaria of rheumatic fever is effective. It is superior to Ebastine group in rapidly improving the pruritus, reducing the number of wind masses and improving the quality of life in patients with urticaria. The recurrence rate is low and there is no obvious adverse reaction, which is worthy of further clinical application.
【学位授予单位】：安徽中医药大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R758.24
本文编号：2159867
[Abstract]:Objective to treat phenotypic urticaria with Xiaofeng Powder and Ebustine, and to evaluate the time of complete regression, the improvement of pruritus, the improvement of the number of wind mass, the improvement of quality of life and the curative effect of the disease in the treatment of urticaria. Adverse reaction and recurrence rate, analysis of its advantages in the treatment of urticaria, explore the therapeutic effect of integrated Chinese and western medicine therapy. Methods Sixty-three patients with urticaria according to phenotype of rheumatic fever were randomly divided into two groups: treatment group (n = 32) and control group (n = 31). The course of treatment in both groups was two weeks. After 7 days and 14 days, the curative effect was observed once and twice respectively. Before and after treatment, the (UAS) score of urticaria activity, the (DLQI) score of quality of life of skin diseases, the time of complete regression of urticaria symptoms, the improvement of pruritus, the improvement of the number of wind masses, and the curative effect of the disease were compared between the two groups. The adverse reactions during treatment and the recurrence rate of urticaria patients within 1 month and 3 months after treatment were observed. All the obtained data were statistically analyzed by SPSS18.0 software. Results (1) before treatment, (UAS) score, wind mass number score, pruritus symptom score were used in the two groups. There was no significant difference in (DLQI) score of skin diseases between the two groups (P0.05). There was a significant difference between the treatment group and the control group after 7 days of treatment and 14 days after treatment compared with that before treatment (P0.01). In the treatment group and the control group, the (UAS) score of urticaria activity, the score of wind mass number, the score of pruritus symptom, the score of quality of life of skin disease, and the curative effect of the disease were compared between the treatment group and the control group after 14 days of treatment and 7 days of treatment. There was significant difference (P0.05). (2) between the two groups after 7 days of treatment of urticaria activity (UAS) score, There was no significant difference in (DLQI) score of skin disease quality of life between the two groups (P0.05), and there was no significant difference in curative effect between the two groups after 7 days of treatment (P0.05). (3). The score of pruritus symptom, the number of wind mass, the (UAS) score of urticaria activity after 14 days of treatment were not statistically significant between the two groups (P0.05). The (DLQI) score of dermatosis quality of life was statistically significant (P0.05). Two groups of patients after 14 days treatment efficacy was statistically significant (P0.05). In the treatment group, the symptoms of pruritus and the number of wind masses were improved by DLQI score and UAS score. (4) the mean time of complete disappearance of symptoms in the treatment group was 6.96 卤2.90 days, and that in the control group was 8.95 卤3.73 days. The difference was statistically significant (P0.05). This suggests that the treatment group took time to quickly improve the symptoms of urticaria. (5) there was no significant difference in the distribution of adverse reactions between the two groups in the course of treatment (P0.05). (6). There was no significant difference in the recurrence rate within one month after treatment between the two groups (P0.05); the recurrence rate within 3 months after treatment had no statistical significance (P0.05). Conclusion the curative effect of Xiaofengsan plus subtractive prescription combined with Ebastine in the treatment of phenotypic urticaria of rheumatic fever is effective. It is superior to Ebastine group in rapidly improving the pruritus, reducing the number of wind masses and improving the quality of life in patients with urticaria. The recurrence rate is low and there is no obvious adverse reaction, which is worthy of further clinical application.
【学位授予单位】：安徽中医药大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R758.24
【参考文献】
相关期刊论文 前10条
1 温炬;陈宝田;李慧;林中方;阮一民;马静;冯洁莹;;消风散对Ⅰ型变态反应的实验研究[J];南方医科大学学报;2009年11期
2 温炬;陈宝田;兰海梅;李慧;林中方;阮一民;马静;冯洁莹;;消风散抗炎活性的动物实验研究[J];广东医学;2009年12期
3 贺学荣;何川;龚建平;;肥大细胞激活机制与变态反应性疾病关系的研究进展[J];重庆医学;2014年09期
4 曾黎峰;钱金荣;;慢性荨麻疹过敏原检测的结果分析[J];实验与检验医学;2011年06期
5 吴伊旋;沈惠风;;慢性荨麻疹部分发病机制的研究进展[J];临床皮肤科杂志;2008年02期
6 周萍;卡介菌多糖核酸用于慢性荨麻疹治疗的效果观察[J];现代实用医学;2005年07期
7 邹维宇;向亚君;吴兴立;廖品东;;廖品东运用小儿推拿治疗小儿荨麻疹临床经验[J];湖北中医杂志;2014年02期
8 任晓丽;苏振兴;刘宏业;白莉;;幽门螺杆菌感染与慢性荨麻疹相关关系的临床观察[J];实用皮肤病学杂志;2012年06期
9 曾宪斌;冯林;;消风散颗粒对肥大细胞脱颗粒的抑制作用[J];江西中医学院学报;2008年01期
10 唐春蕾,刘新国,刘丽君;针刺治疗慢性荨麻疹80例[J];中国针灸;2005年04期
，本文编号：2159867
本文链接：https://www.wllwen.com/yixuelunwen/pifb/2159867.html
最近更新
教材专著
